ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Reardon, DA; Schuster, J; Tran, DD; Fink, KL; Nabors, LB; Li, G; Bota, DA; Lukas, RV; Desjardins, A; Ashby, LS; Duic, JP; Mrugala, MM; Werner, A; Hawthorne, T; He, Y; Green, JA; Yellin, MJ; Turner, CD; Davis, TA; Sampson, JH

Published Date

  • May 20, 2015

Published In

Volume / Issue

  • 33 / 15_suppl

Start / End Page

  • 2009 - 2009

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2015.33.15_suppl.2009